January 2016 in “The Korean Journal of Internal Medicine” Doxazosin may cause breast enlargement and pain in men.
October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
September 2015 in “한국임상약학회지” The document's conclusion cannot be determined without content.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
November 2014 in “British Journal of Dermatology” Male hair loss is mainly due to thinner hair, not less hair.
September 2014 in “PubMed Central” BPH treatments can cause sexual side effects affecting quality of life.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
January 2014 in “Anales Médicos de la Asociación Médica del Centro Médico ABC” The treatment effectively promoted hair growth with minimal side effects.
The models can help find better inhibitors for conditions like baldness and prostate disorders.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
July 2013 in “Edinburgh Research Archive (University of Edinburgh)” Dutasteride may reduce insulin sensitivity and increase body fat.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
December 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” There are several promising treatments for hair loss, including dutasteride, latanoprost, ketoconazole shampoo, anti-androgens, laser/light treatment, and platelet-rich plasma, but more research is needed.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
January 2006 in “Zhongguo yaofang” The market for these drugs is expected to grow.
Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.
July 2002 in “Journal of cosmetic dermatology” Hair loss can be treated with medications like finasteride and surgical methods like hair transplants.
December 2022 in “JAMA network open” 5α-Reductase inhibitors may increase depression risk but not dementia or suicide.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
November 2021 in “Elsevier eBooks” Antiandrogens are used to manage polycystic ovary syndrome by reducing androgen levels or controlling their effects, often combined with lifestyle changes and other treatments.
May 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Clinicians need to better understand and treat Post-finasteride syndrome.
April 2021 in “Journal of Cosmetic Dermatology” Stem cell treatment improved hair density in female hair loss patient.
July 2020 in “Vestnik urologii” The cause of post-finasteride syndrome is unclear and needs more research.
May 2017 in “Journal of The American Academy of Dermatology” Finasteride and dutasteride increase sexual dysfunction reports.